Portola and Kamada attempt flight through IPO window
This article was originally published in Scrip
Executive Summary
Portola Pharmaceuticals and Kamada are the latest biotechnology companies to perch in the initial public offering window that has been opened by investors eager to cash in on a risky sector, which is benefitting from a trend toward more frequent US FDA approvals.